Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 06, 2015 11:10 AM ET


Company Overview of Eleven Biotherapeutics, Inc.

Company Overview

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its product candidates include EBI-005, a novel interleukin-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and has completed Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-031, a novel inhibitor of the cytokine interleukin-6 for the treatment of retinal dis...

215 First Street

Suite 400

Cambridge, MA 02142

United States

Founded in 2008

21 Employees





Key Executives for Eleven Biotherapeutics, Inc.

Chief Executive Officer, President and Director
Age: 55
Total Annual Compensation: $570.9K
Chief Financial and Business Officer
Age: 54
Total Annual Compensation: $429.9K
Chief Development Officer
Age: 52
Total Annual Compensation: $198.0K
Chief Scientific Officer
Age: 55
Total Annual Compensation: $402.4K
Compensation as of Fiscal Year 2014.

Eleven Biotherapeutics, Inc. Key Developments

Eleven Biotherapeutics Presents Data on EBI-031 for the Treatment of Diabetic Macular Edema

Eleven Biotherapeutics, Inc. announced the presentation of data for EBI-031, its novel, protein therapeutic IL-6 inhibitor in preclinical development for diabetic macular edema, at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting. These preclinical pharmacokinetic studies with EBI-031, which have been optimized for intravitreal administration using Eleven’s AMP-Rx technology, confirmed the ability of EBI-031 to potently inhibit IL-6 signaling with extended vitreal retention compared to existing therapies. The Company plans to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) by the end of 2015 for clinical development of EBI-031 in diabetic macular edema.

Eleven Biotherapeutics, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Eleven Biotherapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of USD 24468,000 against USD 568,000 a year ago. Loss from operations was USD 7,597,000 compared to USD 7,189,000 a year ago. Net loss was USD 6,524,000 compared to USD 7,222,000 a year ago. Net loss applicable to common stockholders was USD 6,524,000 or USD 0.36 per basic and diluted share compared to USD 7,741,000 or USD 0.80 per basic and diluted share a year ago.

Eleven Announces Encouraging Data from Phase II Allergic Conjunctivitis Study

Eleven Biotherapeutics has announced encouraging data from a Phase II study of EBI-005 in patients with allergic conjunctivitis. Clinical data on Eleven's lead drug candidate, EBI-005, the first IL-1 (Interleukin-1) receptor inhibitor designed for topical ocular administration, demonstrated statistically significant improvements in ocular itching, ocular tearing and nasal symptoms associated with the late phase allergen response in patients with allergic conjunctivitis, utilizing a modified direct conjunctival allergen model. Statistically significant improvements in ocular itching (mean change from baseline) compared with vehicle were demonstrated at the final two efficacy time points (p = 0.033 at visit 6 and p = 0.046 at visit 7). Statistically significant improvements in ocular tearing (mean change from baseline) compared with vehicle were demonstrated at the final two efficacy time points (p = 0.027 at visit 6 and p = 0.044 at visit 7). Statistically significant improvements in total nasal symptoms (mean change from baseline) compared with vehicle were demonstrated at the final two efficacy time points (p = 0.004 at visit 6 and p = 0.011 at visit 7). EBI-005 was well tolerated with no treatment related serious adverse events and no evidence of drug specific antibodies.

Similar Private Companies By Industry

Company Name Region
The Institute for Bioanalytics, LLC United States
Bridger Technologies, Inc. United States
Recros Medica, Inc. United States
PhaseRx, Inc. United States
Actinobac Biomed, Inc. United States

Recent Private Companies Transactions

Private Placement
November 25, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eleven Biotherapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at